- Home
- Publications
- Publication Search
- Publication Details
Title
Death receptors as targets in cancer
Authors
Keywords
-
Journal
BRITISH JOURNAL OF PHARMACOLOGY
Volume 169, Issue 8, Pages 1723-1744
Publisher
Wiley
Online
2013-05-03
DOI
10.1111/bph.12238
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Systemic use of tumor necrosis factor alpha as an anticancer agent
- (2015) Nicholas J. Roberts et al. Oncotarget
- Prognostic and therapeutic relevance of c-FLIP in acute myeloid leukaemia
- (2012) Donal McLornan et al. BRITISH JOURNAL OF HAEMATOLOGY
- Phase Ib Study of Drozitumab Combined With First-Line mFOLFOX6 Plus Bevacizumab in Patients with Metastatic Colorectal Cancer
- (2012) Caio M. Rocha Lima et al. CANCER INVESTIGATION
- Cell Death via DR5, but not DR4, Is Regulated by p53 in Myeloma Cells
- (2012) S. Surget et al. CANCER RESEARCH
- Sequential Application of Anticancer Drugs Enhances Cell Death by Rewiring Apoptotic Signaling Networks
- (2012) Michael J. Lee et al. CELL
- dsRNA induces apoptosis through an atypical death complex associating TLR3 to caspase-8
- (2012) Y Estornes et al. CELL DEATH AND DIFFERENTIATION
- First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: A Phase I/II open-label and double-blind study
- (2012) George D. Demetri et al. EUROPEAN JOURNAL OF CANCER
- Phase I Trial and Pharmacokinetic Study of Lexatumumab in Pediatric Patients With Solid Tumors
- (2012) Melinda S. Merchant et al. JOURNAL OF CLINICAL ONCOLOGY
- Kinetics in Signal Transduction Pathways Involving Promiscuous Oligomerizing Receptors Can Be Determined by Receptor Specificity: Apoptosis Induction by TRAIL
- (2012) Eva Szegezdi et al. MOLECULAR & CELLULAR PROTEOMICS
- Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours
- (2011) Y Pan et al. BRITISH JOURNAL OF CANCER
- Cisplatin Restores TRAIL Apoptotic Pathway in Glioblastoma-Derived Stem Cells through Up-regulation of DR5 and Down-regulation of c-FLIP
- (2011) Lijuan Ding et al. CANCER INVESTIGATION
- Drozitumab, a Human Antibody to Death Receptor 5, Has Potent Antitumor Activity against Rhabdomyosarcoma with the Expression of Caspase-8 Predictive of Response
- (2011) Z. Kang et al. CLINICAL CANCER RESEARCH
- Oxaliplatin Sensitizes Human Colon Cancer Cells to TRAIL Through JNK-Dependent Phosphorylation of Bcl-xL
- (2011) Zineb El Fajoui et al. GASTROENTEROLOGY
- Quercetin-mediated Mcl-1 and survivin downregulation restores TRAIL-induced apoptosis in non-Hodgkin's lymphoma B cells
- (2011) G. Jacquemin et al. HAEMATOLOGICA
- Expression and prognostic value of FAS receptor/FAS ligand and TrailR1/TrailR2 in acute myeloid leukemia
- (2011) Sandra Pordzik et al. Hematology
- Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non–Small-Cell Lung Cancer
- (2011) Jean-Charles Soria et al. JOURNAL OF CLINICAL ONCOLOGY
- Isolated limb perfusion with TNF-alpha and melphalan for distal parts of the limb in soft tissue sarcoma patients
- (2011) Jan P. Deroose et al. JOURNAL OF SURGICAL ONCOLOGY
- TRAIL-R4 Promotes Tumor Growth and Resistance to Apoptosis in Cervical Carcinoma HeLa Cells through AKT
- (2011) Najoua Lalaoui et al. PLoS One
- Regulating TRAIL Receptor-Induced Cell Death at the Membrane: A Deadly Discussion
- (2011) Sarah Shirley et al. Recent Patents on Anti-Cancer Drug Discovery
- Long-Term Results of Melphalan-Based Isolated Limb Perfusion With or Without Low-Dose TNF for In-Transit Melanoma Metastases
- (2010) Carlo Riccardo Rossi et al. ANNALS OF SURGICAL ONCOLOGY
- A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma
- (2010) A Younes et al. BRITISH JOURNAL OF CANCER
- Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer
- (2010) T Trarbach et al. BRITISH JOURNAL OF CANCER
- Phase I Trial of Weekly Tigatuzumab, an Agonistic Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5)
- (2010) Andres Forero-Torres et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors
- (2010) T. Doi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Up-regulation of death receptor 4 and 5 by celastrol enhances the anti-cancer activity of TRAIL/Apo-2L
- (2010) Hong Zhu et al. CANCER LETTERS
- Multivalent DR5 Peptides Activate the TRAIL Death Pathway and Exert Tumoricidal Activity
- (2010) V. Pavet et al. CANCER RESEARCH
- Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level
- (2010) A Morizot et al. CELL DEATH AND DIFFERENTIATION
- Combining naturally occurring polyphenols with TNF-related apoptosis-inducing ligand: a promising approach to kill resistant cancer cells?
- (2010) Guillaume Jacquemin et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies
- (2010) D. R. Camidge et al. CLINICAL CANCER RESEARCH
- A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors
- (2010) R. S. Herbst et al. CLINICAL CANCER RESEARCH
- TRAIL-Induced Apoptosis Is Preferentially Mediated via TRAIL Receptor 1 in Pancreatic Carcinoma Cells and Profoundly Enhanced by XIAP Inhibitors
- (2010) D. Stadel et al. CLINICAL CANCER RESEARCH
- Expression, Cellular Distribution, and Prognostic Relevance of TRAIL Receptors in Hepatocellular Carcinoma
- (2010) L. Kriegl et al. CLINICAL CANCER RESEARCH
- Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer
- (2010) Jean-Charles Soria et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer
- (2010) Roy S. Herbst et al. JOURNAL OF CLINICAL ONCOLOGY
- TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5
- (2010) Johannes Lemke et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Human monomeric antibody fragments to TRAIL-R1 and TRAIL-R2 that display potent in vitro agonism
- (2010) Claire L. Dobson et al. mAbs
- APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo
- (2010) G. Eisele et al. NEURO-ONCOLOGY
- Predominant antitumor effects by fully human anti-TRAIL-receptor2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo
- (2010) M. Nagane et al. NEURO-ONCOLOGY
- Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors
- (2009) H. A. Wakelee et al. ANNALS OF ONCOLOGY
- Enhancement of Antitumor Properties of rhTRAIL by Affinity Increase toward Its Death Receptors†
- (2009) Carlos R. Reis et al. BIOCHEMISTRY
- Nutlin-3 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through up-regulation of death receptor 5 (DR5) in human sarcoma HOS cells and human colon cancer HCT116 cells
- (2009) Takeshi Hori et al. CANCER LETTERS
- Radiation and anticancer drugs can facilitate mitochondrial bypass by CD95/Fas via c-FLIP downregulation
- (2009) I Verbrugge et al. CELL DEATH AND DIFFERENTIATION
- Proapoptotic signalling through Toll-like receptor-3 involves TRIF-dependent activation of caspase-8 and is under the control of inhibitor of apoptosis proteins in melanoma cells
- (2009) A Weber et al. CELL DEATH AND DIFFERENTIATION
- Combining Radiotherapy with APO010 in Cancer Treatment
- (2009) I. Verbrugge et al. CLINICAL CANCER RESEARCH
- Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study
- (2009) C. H. Mom et al. CLINICAL CANCER RESEARCH
- Prognostic Value of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) and TRAIL Receptors in Renal Cell Cancer
- (2009) S. Macher-Goeppinger et al. CLINICAL CANCER RESEARCH
- c-FLIPL expression defines two ovarian cancer patient subsets and is a prognostic factor of adverse outcome
- (2009) Marina Bagnoli et al. ENDOCRINE-RELATED CANCER
- The extrinsic apoptosis pathway and its prognostic impact in ovarian cancer
- (2009) Evelien W. Duiker et al. GYNECOLOGIC ONCOLOGY
- Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic Study
- (2009) Stephen Leong et al. JOURNAL OF CLINICAL ONCOLOGY
- Expression and biological significance of c-FLIP in human hepatocellular carcinomas
- (2009) Xilin Du et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer
- (2009) Tom M. Ganten et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Prognostic role of myeloid cell leukemia-1 protein (Mcl-1) expression in human gastric cancer
- (2009) Wang Likui et al. JOURNAL OF SURGICAL ONCOLOGY
- Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancer
- (2009) I. Zinonos et al. MOLECULAR CANCER THERAPEUTICS
- Recruitment of the Linear Ubiquitin Chain Assembly Complex Stabilizes the TNF-R1 Signaling Complex and Is Required for TNF-Mediated Gene Induction
- (2009) Tobias L. Haas et al. MOLECULAR CELL
- A novel humanized anti-human death receptor 5 antibody CS-1008 induces apoptosis in tumor cells without toxicity in hepatocytes
- (2008) A. Yada et al. ANNALS OF ONCOLOGY
- Hydrogen peroxide enhances TRAIL-induced cell death through up-regulation of DR5 in human astrocytic cells
- (2008) Daeho Kwon et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers
- (2008) C. Pepper et al. BLOOD
- Role and prognostic significance of tumor necrosis factor‐related apoptosis‐inducing ligand death receptor DR5 in nonsmall‐cell lung cancer and precursor lesions
- (2008) Wendy A. Cooper et al. CANCER
- A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies
- (2008) S. J. Hotte et al. CLINICAL CANCER RESEARCH
- Cooperation of the Agonistic DR5 Antibody Apomab with Chemotherapy to Inhibit Orthotopic Lung Tumor Growth and Improve Survival
- (2008) H. Jin et al. CLINICAL CANCER RESEARCH
- Perifosine Synergistically Enhances TRAIL-Induced Myeloma Cell Apoptosis via Up-Regulation of Death Receptors
- (2008) E. David et al. CLINICAL CANCER RESEARCH
- Prognostic significance of TRAIL-R1 and TRAIL-R3 expression in metastatic colorectal carcinomas
- (2008) Virginie Granci et al. EUROPEAN JOURNAL OF CANCER
- Enhancement of Glioma Radiotherapy and Chemotherapy Response With Targeted Antibody Therapy Against Death Receptor 5
- (2008) John B. Fiveash et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Ligand-Based Targeting of Apoptosis in Cancer: The Potential of Recombinant Human Apoptosis Ligand 2/Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (rhApo2L/TRAIL)
- (2008) Avi Ashkenazi et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer
- (2008) F. Anthony Greco et al. LUNG CANCER
- Nuclear and cytoplasmic death receptor 5 as prognostic factors in patients with non-small cell lung cancer treated with chemotherapy
- (2008) Katharina Leithner et al. LUNG CANCER
- A mitochondrial block and expression of XIAP lead to resistance to TRAIL-induced apoptosis during progression to metastasis of a colon carcinoma
- (2008) O Ndozangue-Touriguine et al. ONCOGENE
- p53-Mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells
- (2008) F Toscano et al. ONCOGENE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started